Fibrin-associated Plasminogen Activation in Alpha 2-plasmin Inhibitor Deficiency
Overview
Authors
Affiliations
The clot formed from the plasma of a patient with congenital deficiency of alpha 2-plasmin inhibitor underwent a spontaneous extensive fibrinolysis. Radiolabeled fibrinogen was added to the plasma before clotting, and the whole process of the fibrinolysis was followed by measuring the release of radiolabels. Plasminogen activation was also followed by measuring the amidolytic activity that developed. There was an initial latent period, followed by an exponential increase of fibrinolytic activity. During the latent period, there was little or no release of radiolabels and no development of amidolytic activity. During the latent period, the clot was washed thoroughly to remove unbound proteins from fibrin and was incubated in buffered saline. The washed clot still underwent fibrinolysis, similar to the original plasma clot, suggesting that the plasminogen/plasminogen activators bound to fibrin during the initial latent period are responsible for fibrinolysis. The amount of plasminogen bound to fibrin during the latent period was close to the amount of plasminogen activated during the whole process of fibrinolysis. When the amount of plasminogen bound to fibrin was decreased by epsilon aminocaproic acid, the extent of fibrinolysis was decreased in parallel with the decrease of the amount of the bound plasminogen. This suggests that the amount of plasminogen bound to fibrin is one of the determinants of the rate of the fibrinolytic process.
Generation of Rapid and High-Quality Serum by Recombinant Prothrombin Activator Ecarin (RAPClot™).
Zhao K, Dimeski G, Masci P, Johnson L, Wang J, de Jersey J Biomolecules. 2024; 14(6).
PMID: 38927049 PMC: 11201583. DOI: 10.3390/biom14060645.
Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery.
Ide M, Bolliger D, Taketomi T, Tanaka K J Anesth. 2009; 24(1):96-106.
PMID: 20039075 DOI: 10.1007/s00540-009-0866-9.
Sazonova I, McNamee R, Houng A, King S, Hedstrom L, Reed G J Thromb Haemost. 2009; 7(8):1321-8.
PMID: 19566545 PMC: 3911889. DOI: 10.1111/j.1538-7836.2009.03491.x.
Organization of the human alpha 2-plasmin inhibitor gene.
Hirosawa S, Nakamura Y, Miura O, Sumi Y, Aoki N Proc Natl Acad Sci U S A. 1988; 85(18):6836-40.
PMID: 3166140 PMC: 282073. DOI: 10.1073/pnas.85.18.6836.
Localization of the binding site of tissue-type plasminogen activator to fibrin.
Ichinose A, Takio K, Fujikawa K J Clin Invest. 1986; 78(1):163-9.
PMID: 3088041 PMC: 329545. DOI: 10.1172/JCI112546.